AFP and cancer: With this aim, Sim et al. [18] have recently designed novel nanoplasmonic chip-based biosensors for the label-free specific detection and quantification of three different targeted cancer biomarkers (i.e., AFP, carcinoembryonic antigen (CEA) and PSA from patient-mimicked serum samples), chosen herein as a “proof-of-concept”.